{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-356947","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2021-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.573961+00:00","generated_at":"2026-06-28T01:15:25.510477+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fate Therapeutics reports positive FT516 and FT596 Phase 1 data; FT516 gets RMAT designation for DLBCL","bullets":["FT516: 6 of 10 CAR T-naive patients in ongoing response at median 9.1 months; 3 of 8 prior CAR T patients achieve CR.","FDA granted RMAT designation for FT516 in relapsed/refractory DLBCL; dose expansion at 900M cells/dose initiated.","FT596: 5 of 6 patients achieve objective response (4 CR) with single dose at 900M cells in combination with rituximab.","FT596: 10 of 11 patients treated with second cycle continue in ongoing response; 3 in CR ≥6 months. No ICANS or GvHD observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-356947","json":"https://secwatch.observer/filing/0001193125-21-356947.json","markdown":"https://secwatch.observer/filing/0001193125-21-356947.md","text":"https://secwatch.observer/filing/0001193125-21-356947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312521356947/0001193125-21-356947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312521356947/d267979d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:15:25.510477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}